Aesica Pharmaceuticals

What Aesica Pharmaceuticals does

Aesica Pharmaceuticals Ltd. is a United Kingdom-based pharmaceutical contract development and manufacturing organization (CDMO) that develops, manufactures, and supplies active pharmaceutical ingredients (APIs), formulations, and custom synthesis services. Founded in 2004 and headquartered in Newcastle Upon Tyne, the company operates with a workforce of 5,001–10,000 employees and serves pharmaceutical clients requiring API production, finished dosage form manufacturing, and bespoke chemistry services.

The company's revenue mechanics are characteristic of a CDMO model: multi-year supply and development contracts with pharmaceutical companies, with pricing typically structured around project milestones, volume commitments, and development fees. Aesica's GTM motion relies on its UK-based manufacturing infrastructure and regulatory track record to win custom synthesis and API supply mandates. The company was founded by Robert Hardy and has Nick Jones serving as CFO; it is privately held with no public ticker. Historical strategic moves include the 2010 acquisition of R5 Pharmaceuticals Ltd. and a 2011 funding round backed by Silverfleet Capital, both of which signaled an expansion-era trajectory.

The source material also references a broader affiliated CDMO platform spanning oral solids, sterile fill-finish, and advanced biotherapeutics (ATMPs, xRNA, viral vectors) across 17 facilities in 8 countries, suggesting Aesica's operations sit within a larger manufacturing network. No specific customers, pricing tiers, or revenue figures are disclosed in the input.

Name

Aesica Pharmaceuticals

Legal name

Recipharm AB

Website

https://aesica-pharma.co.uk

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Aesica Pharmaceuticals is a UK-based pharmaceutical CDMO founded in 2004 that develops, manufactures, and supplies active pharmaceutical ingredients, formulations, and custom synthesis services to pharmaceutical clients.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Small-Molecule API Commercial Manufacturing (HLAGAHAB), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Active pharmaceutical ingredients
• Contract pharmaceutical manufacturing
• Custom synthesis services
• Formulation development
• Sterile fill finish

Headquarters

HQ city

Newcastle Upon Tyne

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure

Core offering

Aesica Pharmaceuticals develops, manufactures, and supplies active pharmaceutical ingredients (APIs), finished dosage formulations, and custom synthesis services to pharmaceutical companies. The company also provides sterile fill-finish, advanced therapy medicinal product (ATMP) manufacture, and supporting development and regulatory services as part of a broader CDMO platform.

Product overview

Recipharm operates as a global CDMO (Contract Development and Manufacturing Organization) offering end-to-end pharmaceutical development and manufacturing solutions. The company provides a platform-plus-services architecture comprising three core product areas: Solids & Others (oral solid dosage forms, semi-solids, liquids, pharmaceutical packaging, and controlled drugs), Sterile Delivery (sterile fill-finish including vials, prefilled syringes, cartridges, lyophilisation, blow-fill-seal, ampoules, and specialized services for ophthalmics, beta-lactams, and vaccines), and Advanced Bio (ATMPs including xRNA therapies, virus and viral vectors, microbial and live biotherapeutic products, and recombinant proteins). Additional services include ReciPredict value design, analytical services, regulatory excellence support, and new product introduction services including technology transfer and product development. The company operates 17 facilities across 8 countries serving over 100 markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Solids & Others

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Broad incumbents

• Lonza Group: World-leading CDMO across small molecules, biologics, and cell & gene therapies. Comparable to Aesica/Recipharm in API manufacturing and increasingly in sterile/advanced modalities.
• Thermo Fisher Scientific (Patheon): Operates one of the world's largest CDMO networks via Patheon, covering small molecules, biologics, sterile fill-finish, and viral vectors. A scaled incumbent competing with Aesica/Recipharm across virtually every modality.
• Catalent: Global CDMO providing softgel, oral solids, sterile fill-finish, and biologics services. Directly comparable to Aesica's small-molecule and formulation CDMO offering but at much larger scale.

Direct peers

• Cambrex: Small-molecule API and finished dosage CDMO with facilities in the US and Europe. Directly comparable to Aesica's API manufacturing and custom synthesis capabilities.
• PCI Pharma Services: Global CDMO offering drug development, manufacturing, and packaging services including sterile fill-finish. Comparable integrated CDMO offering with similar customer base of pharma and biotech sponsors.
• Aenova Group: European-headquartered CDMO offering solid dosage forms, semi-solids, sterile liquids, and API services. Closely comparable size and service mix to Aesica's UK operations.
• Recipharm AB: Recipharm is the parent CDMO group that acquired Aesica. Operates 17 facilities across 8 countries offering solids, sterile fill-finish, and advanced biologics services — a direct small-molecule and biologics CDMO peer.
• Fareva: Privately held European CDMO providing API manufacturing, formulation, sterile fill-finish, and packaging. Similar mid-sized CDMO profile with European manufacturing footprint.
• Vetter Pharma: Specialist CDMO focused on aseptic filling of syringes, cartridges, and vials. Comparable to Aesica/Recipharm's sterile fill-finish and lyophilization capabilities.

Emerging players

• Alcami Corporation: US-headquartered CDMO providing API manufacturing, analytical services, and finished dosage forms. Comparable in small-molecule API and formulation services though more US-centric.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• YouTubeyoutube.com/channel/UCr-bw7pCCkYZfeImOwTfNRg
• LinkedInlinkedin.com/company/aesica-pharma
• Xx.com/aesica

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aesica Pharmaceuticals